Bovilis IBR marker live, lyophilisate and solvent 25 Dose

Target species Cattle. Indications for use Active immunisation of cattle to reduce the intensity and duration of the clinical respiratory signs induced by an infection with BHV-1 and to reduce nasal excretion of field virus. Onset of immunity: An increase in immunity was demonstrated 4 days after intranasal vaccination and 14 days after intramuscular vaccination of 3 month old seronegative animals. Duration of immunity: After intranasal administration to 2 week old calves immunity lasts at least until the age of 3-4 months. In the presence of maternally derived antibodies, the protection of the vaccine may not be complete until a second revaccination. This second vaccination should be administered at 3-4 months of age and will result in protective immunity that lasts for at least 6 months. Single intranasal or intramuscular vaccination of 3 months old animals provides protective immunity (reduction of clinical signs and reduction of viral excretion), which was demonstrated via challenge 3 weeks after vaccination. Reduction of viral excretion is maintained for at least 6 months after single vaccination. Revaccination to ensure protection after the initial 6 month protection period has elapsed will result in protective immunity that lasts for 12 months. Specific information: No information is available on the efficacy of the vaccine to prevent a latent wild virus infection or to prevent wild virus re-excretion in the latent carrier. Contraindications None. Special warnings for each target species The presence of maternal antibodies can influence the efficacy of the vaccination. Therefore it is recommended to ascertain the immune status of calves before vaccination is started. Special precautions for use Vaccinate only healthy animals. After intranasal administration, the vaccine virus may spread to in-contact cattle. Cattle which need to remain totally free from BHV‑1 antibodies should be separated from intranasally vaccinated animals. Operator warnings In case of accidental self injection, seek medical advice immediately and show the package leaflet or the label to the physician. Adverse reactions A slight transient rise in temperature (1 °C) can commonly occur up to 5 days post vaccination. An increase of nasal discharge can be commonly observed after intranasal vaccination. In very rare cases hypersensitivity reactions can occur. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports). Use during pregnancy or lactation Can be used during pregnancy and lactation. No information is available on the use of this vaccine in breeding bulls. Interactions Safety and efficacy data -in cattle from 3 weeks of age onwards- are available which demonstrate that this vaccine can be administered on the same day but not mixed with Bovilis Bovipast RSP. Safety and efficacy data are available which demonstrate that for the intramuscular revaccination - in cattle from 15 months of age onwards (i.e. those that have previously been vaccinated separately with Bovilis IBR Marker Live and Bovilis BVD) - this vaccine can be mixed and administered with Bovilis BVD. The product literature of Bovilis BVD should be consulted before administration of the mixed products. The adverse effects observed after administration of one dose or an overdose of the mixed vaccines are not different from those described for the vaccines administered separately. When mixed with Bovilis BVD at re-vaccination, the demonstrated efficacy claims for Bovilis IBR Marker Live are as follows: - Active immunisation of cattle to reduce the fever induced by an infection with BHV-1 and to reduce nasal excretion of field virus. - Duration of immunity : 12 months demonstrated by serological data. No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis. Do not use together with immunosuppressive agents.